Alector initiates phase 1 clinical trial of al044 for the treatment of alzheimer's disease (ad)

Al044 is the first clinical-stage drug candidate targeting ms4a, a major genetic risk factor for ad
ALEC Ratings Summary
ALEC Quant Ranking